Technological advances in mucositis research: New insights and new issues

Cancer Treatment Reviews

Volumn 34, Issue 5, 2008, Pages 476-482

  Gibson, Rachel J ^a,b   Bowen, Joanne M ^a,b   Keefe, Dorothy M K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Chemotherapy; Gastrointestinal tract; Microarray; Mucositis

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CETUXIMAB; COMPLEMENTARY DNA; CYTOKINE; CYTOTOXIC AGENT; FLUOROURACIL; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MATRIX METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; PALIFERMIN; PEMETREXED; POTASSIUM CHANNEL HERG; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SUNITINIB; TRASTUZUMAB;

ANTIANGIOGENIC ACTIVITY; CLINICAL LABORATORY; DNA MICROARRAY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; ENTERITIS; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; INFECTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NANOMEDICINE; NANOTECHNOLOGY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOGENETICS;

BIOMEDICAL RESEARCH; GENE THERAPY; GENETIC TECHNIQUES; HUMANS; MUCOSITIS; NEOPLASMS; PROGNOSIS;

EID: 46749090072     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.02.001     Document Type: Review

References (65)

1. Bowen J.M., Gibson R.J., Keefe D.M., and Cummins A.G. Cytotoxic chemotherapy increases proapoptotic Bax and Bak expression in crypts of the rat and human small intestine. Pathology 37 (2005) 56-62
2. Keefe D.M., Brealey J., Goland G.J., and Cummins A.G. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 47 (2000) 632-637
3. Gibson RJ. Chemotherapy induced mucositis: mechanisms of damage, time course of events and possible preventative strategies. PhD Thesis, Department of Medicine, University of Adelaide; 2004. p. 150.
4. Gibson R.J., Bowen J.M., Inglis M.R., Cummins A.G., and Keefe D.M.K. Irinotecan causes severe small intestinal damage as well as colonic damage in the rat with implanted breast cancer. J Gastroenterol Hepatol 18 (2003) 1095-1100
5. Pico J.L., Avila-Garavito A., and Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3 (1998) 446-451
6. Keefe D.M., Cummins A.G., Dale B.M., Kotasek D., Robb T.A., and Sage R.E. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci 92 (1997) 385-389
7. Savarese D.M., Hsieh C., and Stewart F.M. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 15 (1997) 2981-2995
8. Elting L.S., Cooksley C., Chambers M., Cantor S.B., Manzullo E., and Rubenstein E.B. The burdens of cancer therapy, clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (2003) 1531-1539
9. Barasch A., and Peterson D.E. Risk factors for ulcerative mucositis in cancer patients: unanswered questions. Oral Oncol 39 (2003) 91-100
10. In: Sonis S.T., Peterson D.E., McGuire D.B., and Williams D.A. (Eds). Mucosal injury in cancer patients: new strategies for research and treatment vol. 29 (2001), Oxford University Press JNCI, Bethesda 1-2 [editorial]
11. Keefe DMK, The effect of cytotoxic chemotherapy on the mucosa of the small intestine. MD Thesis, Department of Medicine, University of Adelaide; 1998. 235p. Available from: .
12. Sloan J.A., Goldberg R.M., Sargent D.J., Vargas-Chanes D., Nair S., Cha S.S., et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20 (2002) 1491-1498 [comment]
13. Sonis S., Haddad R., Posner M., Watkins B., Fey E., Morgan T.V., et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol 43 (2007) 289-300
14. Trier J.S. Morphological alterations induced by methotrexate in the mucosa of human proximal intestine I. Serial observations by light microscopy. Gastroenterology 42 (1962) 295-305
15. Trier J.S. Morphologic alterations induced by methotrexate in the mucosa of human proximal intestine II. Electron microscopic observations. Gastroenterology 43 (1962) 407-424
16. Sonis S.T., Tracey C., Shklar G., Jenson J., and Florine D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69 (1990) 437-443
17. Sonis S.T., Costa J.W., Evitts S.M., Lindquist L.E., and Nicolson M. Effect of epidermal growth factor on ulcerative mucositis in hamsters that receive cancer chemotherapy. Oral Surg Oral Med Oral Pathol 74 (1992) 749-755
18. Sonis S.T., Lindquist L., Van Vugt A., Stewart A.A., Stam K., Qu G.Y., et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 54 (1994) 1135-1138
19. Sonis S., Edwards L., and Lucey C. The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 13 (1999) 831-834
20. Sonis S.T. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34 (1998) 39-43
21. Logan R.M., Gibson R.J., Sonis S.T., and Keefe D.M. Nuclear factor kB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43 (2007) 395-401
22. Gibson R.J., Cummins A.G., Bowen J.M., Logan R.M., Healey T., and Keefe D.M.K. Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pac J Clin Oncol 2 (2006) 39-49
23. Yeoh A.S., Bowen J.M., Gibson R.J., and Keefe D.M. Nuclear factor kappaB (NFkappaB) and cyclooxygenase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 63 (2005) 1295-1303
24. Gibson R.J., Bowen J.M., and Keefe D.M. Palifermin reduces diarrhoea and increases survival following irinotecan treatment in tumour-bearing DA rats. Int J Cancer 116 (2005) 464-470
25. Gibson R.J., Bowen J.M., Cummins A.G., and Keefe D.M. Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med 4 (2005) 188-195
26. Gibson R.J., Keefe D.M.K., Thompson F.M., Clarke J.M., Goland G.J., and Cummins A.G. Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47 (2002) 2751-2757
27. Gibson R.J., and Keefe D.M.K. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14 (2006) 890-900
28. Bowen J.M., Gibson R.J., Cummins A.G., and Keefe D.M.K. Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 17 (2006) 713-731
29. Keefe D.M., Gibson R.J., and Hauer-Jenson M. Gastrointestinal mucositis. Sem Oncol Nurs 20 (2004) 38-47
30. Sonis S.T., Elting L.S., Keefe D., Peterson D.E., Schubert M., Hauer-Jensen M., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 (2004) 1995-2025
31. Sonis S.T. The pathobiology of mucositis. Nat Rev Cancer 4 (2004) 277-284
32. Sonis S.T. A biological approach to mucositis. J Support Oncol 2 (2004) 21-32 [discussion: 35-6]
33. Sonis S.T. Pathobiology of mucositis. Semin Oncol Nurs 20 (2004) 11-15
34. Schena M., Shalon D., Davis R.W., and Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 (1995) 467-470
35. Hoffman W.J. Introduction. In: Hoffman W.J. (Ed). Gene expression profiling by microarrays: clinical implications (2006), Cambridge University Press, Cambridge 246 pp
36. Arcellana-Panlilio M., and Robbins S.M. Cutting-edge technology. I. Global gene expression profiling using DNA microarrays. Am J Physiol Gastro Liver Physiol 282 (2002) G397-G402
37. Keefe D.M.K., and Gibson R.J. Mucosal injury from targeted anti-cancer therapy. Support Care Cancer 15 (2006) 483-490
38. Weiner L.M. Fully human therapeutic monoclonal antibodies. J Immunother 29 (2006) 1-9
39. Ito Y., Tokudome N., Sugihara T., Takahashi S., and Hatake K. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?. Breast Can 14 (2007) 156-162
40. Becker J.C., Muller-Tidow C., Serve H., Domschke W., and Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12 (2006) 3297-3305
41. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6 (2006) 714-721
42. Morabito A., De Maio E., Di Maio M., Normanno N., and Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11 (2006) 753-764
43. Lowndes S., Darby A., Mead G., and Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13 (2002) 1948-1950
44. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 27 (2000) 20-26
45. Robert F., Blumenschein G., Herbst R.S., Fossella F.V., Tseng J., Saleh M.N., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 9089-9096
46. Homsi J., and Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Can Cont 14 (2007) 285-294
47. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97 (2000) 12329-12333
48. Moghimi S.M., Hunter A.C., and Murray J.C. Nanomedicine: current status and future prospects. FASEB J 19 (2005) 311-330
49. Rha S.Y., Jeung H.C., Choi Y.H., Yang W.I., Yoo J.H., Kim B.S., et al. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12 (2007) 622-630
50. Watters J.W., and McLeod H.L. Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603 (2003) 99-111
51. Cusatis G., Gregorc V., Li J., Spreafico A., Ingersoll R.G., Verweij J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98 (2006) 1739-1742
52. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54 (2005) 171-196
53. Abraham J., Earl H.M., Pharoah P.D., and Caldas C. Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 1766 (2006) 168-183
54. Zhang M.Q. Large-scale gene expression data analysis: a new challenge to computational biologists. Genome Res 9 (1999) 681-688
55. Chiappelli F. The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. Evid Based Complement Alternat Med 2 (2005) 489-494
56. Bogunia-Kubik K., Polak M., and Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 617-622
57. Bogunia-Kubik K., Suchnicki K., and Lange A. HLA-DR11 in addition to donor age, gender, and major blood group incompatibility influence the incidence of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplant Proc 35 (2003) 1556-1558
58. Przekop Jr. P.R., Tulgan H., Przekop A.A., and Glantz M. Adverse drug reaction to methotrexate: pharmacogenetic origin. J Am Osteopath Assoc 106 (2006) 706-707
59. Bowen J.M., Gibson R.J., Cummins A.G., Tyskin A., and Keefe D.M. Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol 59 (2007) 337-348
60. Bowen J.M., Gibson R.J., Tsykin A., Stringer A.M., Logan R.M., and Keefe R.M. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 121 (2007) 1847-1856
61. Sonis S.T. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13 (2002) 380-389
62. Pritchard D.M., Potten C.S., and Hickman J.A. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res 58 (1998) 5453-5465
63. Pritchard D.M., Print C., O'Reilly L., Adams J.M., Potten C.S., and Hickman J.A. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 19 (2000) 3955-3959
64. Sonis S.T., Scherer J., Phelan S., Lucey C.A., Barron J.E., O'Donnell K.E., et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Proliferation 35 (2002) 93-102
65. Logan R.M., Stringer A.M., Bowen J.M., Yeoh A.S., Gibson R.J., Sonis S.T., et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33 (2007) 448-460